Akademik Veri Yönetim Sistemi
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.27, sa.3, ss.150-160, 2017 (SCI-Expanded)
In this study, one hundred patients under 65 years of age, who were diagnosed with acute myeloid leukemia (AML) between June 2008 to December 2015 were evaluated retrospectively. Diagnosis of the patients were based on WHO 2008 acute leukemia diagnosis criteria. One hundred AML patients were anlayzed on the basis of gender, hemoglobin levels < 10 and >= 10 g/dL and ECOG performans status < 2 and >= 2, blast count in bone marrow (BM) <%30 and >=%30, auer body presence, cytogenetics, CD56, CD19, CD2, CD7, Tdt expression, morphological types and treatment response. 52% was male and mean age at diagnosis was 49 +/- 11.4 (18-62) years. Response to induction therapy; complete response was 53%, non-response was 16% and death during the induction phase was 31%. At the end of the study analyses, 35% of patients was in remission and 65% was dead. A multivariate Cox regression analysis revealed gender (p=0.038, HR=0.568, 95% CI: 0.332-0.97), lactate dehydrogenase (LDH) levels (p < 0.0001, HR=1.00, 95% CI: 1.000-1.001), fibrinogen levels (p=0.003, HR=1.002, 95% CI: 1.001-1.004), BM fibrosis (p < 0.0001, HR=4.098, 95% CI: 2.287-7.345), cytogenetic risk classification (p=0.056, HR=1.486, 95% CI: 0.990-2.231), fungal infection (p=0.002, HR=0.348, 95% CI: 0.179-0.677) as prognostic factors. Aberrant expression of CD2, CD7, CD19 and CD56 on AML cells were not a poor prognostic factor in this study. Gender, LDH levels, fibrinogen levels, cytogenetic risk classification, presence of fibrosis in BM and fungal infection was found to be independent risk factors on mortality in AML patients.